Boehringer Ingelheim and Priaxon entered into a worldwide collaboration to research and develop mdm2/p53 inhibitors for the treatment of cancer. It has been shown that in tumors with wild-type p53, the restoration of p53 tumor-suppressive functions can be achieved by blocking a cellular interaction of mdm2 and p53, the companies explain.
Priaxon is providing its small molecule drug discovery expertise. Boehringer Ingelheim will provide up-front and near-term fees including research funding to support further discovery efforts. In addition, Priaxon will be eligible to receive €86 million (about $123.7 million) in milestones upon achievement of certain development, regulatory, and commercial goals as well as royalties on potential future net sales of products.
The companies will work jointly to identify and advance candidates into preclinical development. Thereafter, Boehringer Ingelheim will drive the development and commercialization of the potential cancer treatments arising from the collaboration.
“Using the strength of its unique drug-discovery platforms, Priaxon was able to develop new promising mdm2/p53 inhibitors with high potency,” according to Juergen Kolb, CEO of Priaxon. “Our collaboration with Boehringer Ingelheim and its experts in oncology provides the resources and the capabilities to drive this program forward. Both Boehringer Ingelheim and Priaxon are looking forward to working together with the goal to develop a small molecule inhibitor for this protein-protein interaction of high potential.”